Britain and America have finalized a key commercial pact that will guarantee no duties on British drug shipments going into the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost spending on drugs through the NHS. This move ensures that import taxes on these crucial products will remain at nothing for a duration of 36 months.
This development is in response to recent warnings to significantly raise duties on branded drug imports, with figures mentioned reaching 100%.
"This agreement between the United Kingdom reinforces the international landscape for new treatments and introduces much-needed equity to American-British drug exports," a release said.
Economic Significance
Pharmaceuticals are one of the UK's biggest exports to the America, which is clearly the primary buyer for leading British pharmaceutical firms.
Statistics reveal that in the year leading up to last September, the UK sold medicines valued at £11.1bn to the US. This amount represented 17.4% of British export trade in that timeframe.
"This guarantee protects jobs, increases funding and facilitates the UK to become a global hub for biotech and pharma," the Business and Trade Secretary stated.
Detailed NHS Changes
The pact involves several notable changes from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to increase total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at 15%. Last year, repayments were more than 20%.
Broader Context
The pact comes amid a long-running dispute between the drug companies and the ministers over drug pricing and approval rates.
This friction were exacerbated by arguments that American customers were paying significantly more for the same drugs than consumers in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while substantial investments have been pledged toward projects in the United States.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had decreased as a percentage of its total funding over the past decade.
